• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MedCity News Q&A: Meridian Bioscience CEO Jack Kraeutler

MedCity News Q&A: Meridian Bioscience CEO Jack Kraeutler

February 1, 2010 By MedCity News

By Mary Vanac

MedCity News logo

CINCINNATI, Ohio — Over the years, Meridian Bioscience Inc. has gotten good at making diagnostic test kits that detect bugs like C. difficile and H. pylori, both bacteria that can wreak havoc in the digestive tract — or worse.

The longtime Cincinnati-based life sciences company also knows a lot about testing for upper-respiratory infections, antibodies in the blood, and even for parasites and fungi, as well as supplying big laboratories with the proteins they need to do their work.

Now, the company that sells most of its tests to hospitals, reference laboratories, research centers, doctors’ offices and veterinary testing centers is getting into molecular testing — tests that are so sensitive they can spot a single bacterium or virion in a tiny sample.

CEO Jack Kraeutler talked with MedCity News about the promise of this new generation of diagnostic tests — and potential acquisitions – for his company.

MedCity News: In January, Meridian Bioscience started clincial trials of its molecular test for C. difficile, which like other future molecular tests will will go by the brand name “Illumigene.” What’s the development strategy behind this new platform technology?

Jack Kraeutler: As we move into molecular, there are a couple of detection goals that we have. One is, if it’s a single-point detection, let’s say you’re looking for a virus, that uses a simpler technology. Now, if you’re looking for a virus or a bacteria that might be resistant to a particular drug, now you need to have multi-analyte capability. With the current generation of Illumigene, you could do multi-analyte testing, but it would require two different tests. In the future, we’ll be able to do it in the same test.

MedCity News: So what’s the market opportunity for Illumigene?

JK: For us, the ability to go into molecular gives us, not necessarily a displacement technology, but a technology that augments all of the immunoassays that we sell. The first platform of C. difficile – and that’s the one we expect to launch later this year — is capable of producing somewhere in the range of $10 to $20 million annually. The second generation of Illumigene, which will probably start to go into clinical trials later this fiscal year, should be able to do even more than that.

MedCity News: Is Illumigene part of the medical industry’s move toward personalized medicine?

JK: Many of the most rapidly growing tests are the ones that can be done in 10 or 15 minutes. Most people tend to think of these tests as doctor-office tests. But when you’re dealing with acute diseases, hospitals need to be able to run these tests 24-7 so the right therapies can be selected. That happens to be a type of personalized medicine in the acute-care market.

The interesting thing about Illumigene is that most molecular assays that are in the market are very cumbersome because they’re based on a technology called “polymerase chain reaction." With PCR, you have to raise and lower the temperature of the sample several times to amplify it so that it can be tested. It usually requires large pieces of capital equipment to do PCR.

Our product is run at a constant temperature, and it is simple enough to be run one at a time. There’s no capital equipment associated with it. So it does have a much greater reach.

MedCity News: Tell me about the amplification technology you licensed from Japan that enables you to run samples without thermo-cycling them.

JK: The technology was developed for oyster farmers who were concerned about norovirus contaminating their oyster beds. So they needed a very sensitive technology that would measure down to a single virion in a water sample. And they came up with the LAMP technology, it’s loop-amplification, and we’ve adapted it to human samples.

MedCity News: Now, sales of your current generation of C. difficile test were flat in the fiscal first quarter because of increasing competition. It strikes me that Illumigene could re-energize your test line for this bacteria.

JK: That’s actually been our history. We’ve been detecting C. difficile for almost 20 years now. Every 18 to 24 months, we introduce a new product. So, we’ve had about seven evolutions over the last 20 years. And this, of course, is a major step up. I think Illumigene is a platform that will change the perception of Meridian as being just a little kit company to being a company that is a player with advanced technologies.

MedCity News: What are the major challenges that Meridian Bioscience will face in 2010?

JK: One of the nice things about the business is because it’s built around infectious diseases, it doesn’t ebb and flow because of economic conditions. And in virtually every case, our products help the patient get better faster with the right therapy. So it’s a stable business.

What’s impacting us today is so many companies have tried to go for the high-volume diagnostics. They’re beginning to open their eyes to see our space, which has largely been populated with Meridian and three or four other companies.

The problem is, the technologies these other companies want to bring into our space are extremely expensive. My worry is these companies are going to do stupid things in terms of pricing their products and other taking market share other ways. And it’s going to be disruptive. But this is a fast-moving business, and we can deal with it.

MedCity News: What are the biggest opportunities your company has this year?

JK: One is to increase sales outside the United States. For the first quarter, for example, our international sales were up 17 percent, which was a good number for us. Our international sales increases had been running around 9 or 10 percent. We think we can increase international sales by fine-tuning some of our distributor partnerships. We made some changes in Canada, Australia, Argentina and Israel recently. We’re looking at two other markets.

We also have new product lines, like one that tests for the bacteria that causes most stomach ulcers, H. pylori. And food-borne infections like E. coli and Campylobacter are emerging markets for us that are growing very fast.

There is no silver bullet. This year is about balanced opportunities and making sure that we maximize those opportunities.

MedCity News: Your company has zero debt. What gives?

JK: Any time that we’ve raised debt or borrowed money, we’ve paid it off quickly. And that makes us a shopper this year. We are looking for opportunities. But because we’ve got a financially efficient business, we’re not going to buy something and make our shareholders wait three years for the payback. It has to be accretive in the first year.

MedCity News: Is there a certain type of company that you’re looking for?

JK: We’re looking at businesses that we can bolt into our life sciences business. To make it clear, our life science business is one that supplies the biggest automated diagnostic companies like Abbott, Roche, Johnson & Johnson with their essential proteins. So it’s a limited customer market, it’s a highly technical sale, and the more components and biologics you can offer them, the better that business will grow. So, small, private businesses … $5, $10, $15 million in revenue are excellent bolt-ons for us.

And then there are a number of diagnostic opportunities, either carve-outs that are non-strategic for bigger businesses, or a number of smaller [firms], both public and private, that have been wandering for years and could use a good home.

Filed Under: Business/Financial News, Diagnostics, News Well Tagged With: Meridian Bioscience Inc.

In case you missed it

  • Technical Brief – “Understanding the Extensive OEM Benefits of Total Linear Motion Solutions.”
  • Exactech launches total hip arthroplasty system
  • Lensar announces first patients treated with Ally adaptive cataract treatment
  • HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
  • GE Healthcare leads AliveCor Series F funding for ECG tech
  • New FDA ruling may lower costs for over-the-counter hearing aids
  • Data supports Sight Sciences’ Omni surgical system for glaucoma
  • Integra founder Richard Caruso has died
  • Moximed raises $40M for implantable shock absorber for knee osteoarthritis
  • Philips names Roy Jakobs as CEO amid ventilator, CPAP recalls
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year

RSS From Medical Design & Outsourcing

  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy